Exacerbation of central serous chorioretinopathy following intravitreal triamcinolone injection

Kocabora, Mehmet Selim; Durmaz, Sahan; Kandemir, Nilay

doi:10.1007/s00417-008-0932-2

Cited by 22 publications

(16 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Whether intraocular steroids induce CSCR remains to be demonstrated. The aggravation of a pre-existing CSCR and the induction of a CSCR after vitrectomy and triamcinilone injection have been described in two case reports (Imasawa et al, 2005;Kocabora et al, 2008). A systematic literature search of corticosteroid-induced CSCR reports is summarized in Table 1, indicating the incriminated drugs, routes of intake and doses.…”

Section: Corticosteroidsmentioning

confidence: 97%

Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis

Daruich

Matet

Dirani

et al. 2015

Progress in Retinal and Eye Research

819

996

View full text Add to dashboard Cite

Central serous chorioretinopathy (CSCR) is a major cause of vision threat among middle-aged male individuals. Multimodal imaging led to the description of a wide range of CSCR manifestations, and highlighted the contribution of the choroid and pigment epithelium in CSCR pathogenesis. However, the exact molecular mechanisms of CSCR have remained uncertain. The aim of this review is to recapitulate the clinical understanding of CSCR, with an emphasis on the most recent findings on epidemiology, risk factors, clinical and imaging diagnosis, and treatments options. It also gives an overview of the novel mineralocorticoid pathway hypothesis, from animal data to clinical evidences of the biological efficacy of oral mineralocorticoid antagonists in acute and chronic CSCR patients. In rodents, activation of the mineralocorticoid pathway in ocular cells either by intravitreous injection of its specific ligand, aldosterone, or by over-expression of the receptor specifically in the vascular endothelium, induced ocular phenotypes carrying many features of acute CSCR. Molecular mechanisms include expression of the calcium-dependent potassium channel (KCa2.3) in the endothelium of choroidal vessels, inducing subsequent vasodilation. Inappropriate or over-activation of the mineralocorticoid receptor in ocular cells and other tissues (such as brain, vessels) could link CSCR with the known co-morbidities observed in CSCR patients, including hypertension, coronary disease and psychological stress.

show abstract

Section: Corticosteroidsmentioning

confidence: 97%

Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis

Daruich

Matet

Dirani

et al. 2015

Progress in Retinal and Eye Research

819

996

View full text Add to dashboard Cite

show abstract

“…18,82,100 Intravitreal and periocular steroid treatments are common, yet reports of CSC after local ocular steroid injections are rare; however, almost every form of exogenous glucocorticoid has been associated with exacerbation, and ocular and systemic glucocorticoids should be avoided in CSC.…”

Section: Pathophysiologymentioning

confidence: 99%

Central Serous Chorioretinopathy: Update on Pathophysiology and Treatment

Nicholson

Noble

Forooghian

et al. 2013

Survey of Ophthalmology

562

573

View full text Add to dashboard Cite

Recent technological advances have led to an improved understanding of central serous chorioretinopathy (CSC): new pathophysiological insights, new imaging techniques for diagnosis and management, and new treatments. The primary role of the choroid has become more widely accepted with widespread use of indocyanine green angiography. Optical coherence tomography (OCT), and particularly enhanced depth imaging OCT, demonstrate a thickened and engorged choroid. Adaptive optics, fundus autofluorescence, multifocal electroretinography, microperimetry, and contrast sensitivity testing reveal that patients with even a mild course suffer previously undetected anatomic and functional loss. While focal laser and photodynamic therapy are the current standard of care for persistent subretinal fluid in CSC, they are not appropriate in all cases, and the optimal timing of intervention remains unclear.

show abstract

“…Other studies indicated a statistical significant association between the development of central serous chorioretinopathy and corticosteroid medications administered not only by the oral route but also inhaled, intranasal, epidural, intra‐articular, topical dermal or periocular . Central serous chorioretinopathy development has also been described in two case reports after intraocular triamcinolone injections …”

Section: Discussionmentioning

confidence: 91%

“…18 Central serous chorioretinopathy development has also been described in two case reports after intraocular triamcinolone injections. 8,19 Available data from another populationbased study on the association between topical ophthalmic corticosteroids and central serous chorioretinopathy indicate that patients who had used topical ophthalmic corticosteroids within a year before the index date of diagnosis of central serous chorioretinopathy in the treated eye were at higher risk of developing central serous chorioretinopathy than controls. 20 No data are available regarding development of central serous chorioretinopathy in the fellow eye after topical ophthalmic administration of steroids.…”

Section: Discussionmentioning

confidence: 99%

Central serous chorioretinopathy in the fellow eye as a complication of intravitreal dexamethasone implant for the treatment of Irvine‐Gass syndrome

Georgalas

Petrou

Pagoulatos

et al. 2016

Clinical and Experimental Optometry

View full text Add to dashboard Cite

Exacerbation of central serous chorioretinopathy following intravitreal triamcinolone injection

Abstract: Central serous chorioretinopathy exacerbation may arise as a complication of intravitreal triamcinolone acetonide injection.

Cited by 22 publications

References 11 publications

Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis

Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis

Central Serous Chorioretinopathy: Update on Pathophysiology and Treatment

Central serous chorioretinopathy in the fellow eye as a complication of intravitreal dexamethasone implant for the treatment of Irvine‐Gass syndrome

Contact Info

Product

Resources

About